CZAR-1

Study Design: Phase II, randomized, multicenter, international trial

Patients: treatment naive and relapsed WM patients

Treatment: Carfilzomib/Ibrutinib versus Ibrutinib

Status of the Study: recruiting completed

Sponsor: University Hospital of Ulm, PI Christian Buske

further information